(NASDAQ: ZBIO) Zenas Biopharma's forecast annual revenue growth rate of 97.08% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 64.17%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.07%.
Zenas Biopharma's revenue in 2025 is $5,000,000.On average, 1 Wall Street analysts forecast ZBIO's revenue for 2025 to be $835,986,720, with the lowest ZBIO revenue forecast at $835,986,720, and the highest ZBIO revenue forecast at $835,986,720. On average, 1 Wall Street analysts forecast ZBIO's revenue for 2026 to be $716,440,619, with the lowest ZBIO revenue forecast at $716,440,619, and the highest ZBIO revenue forecast at $716,440,619.
In 2027, ZBIO is forecast to generate $1,700,187,992 in revenue, with the lowest revenue forecast at $1,476,352,548 and the highest revenue forecast at $1,924,023,436.